Key Development During an executive briefing on public health infrastructure strategy released on August 4, 2026, Assoc. Prof. Tang Chi... Read more
Category: Uncategorized
Relieving Capital Healthcare Pressure: National Hospital of Obstetrics and Gynecology Formally Commissions 300-Bed Campus 2 at Hanoi’s Western Gateway
Key Development This morning, August 4, 2026, Campus 2 of the National Hospital of Obstetrics and Gynecology (NHOG) officially opened... Read more
Digital Health Transformation Acceleration: Ministry of Health Tightens Compliance Under Resolution 57, Scaling Electronic Medical Records (EMR) and VNeID Personal Health Records
Key Development On the morning of August 4, 2026, the Ministry of Health (MOH) of Vietnam convened a high-level executive... Read more
Standardizing Pre-Hospital Emergency Infrastructure: HCMC Proposes Clear Regulatory Separation Between Emergency Ambulances and Non-Emergency Patient Transports
Key Development During a strategic working session with the Ministry of Health on August 3, 2026, Assoc. Prof. Tang Chi... Read more
Immediate Regulatory Sanction: Ministry of Health Decrees Nationwide Seizure of Layer Clean Foaming Hand Wash Over Undeclared Preservatives and Unlicensed Manufacturing
Key Development The Drug Administration of Vietnam (DAV), operating under the Ministry of Health, has formally issued an emergency regulatory... Read more
Blockbuster DAC Acquisition: Johnson & Johnson Deploys $1 Billion to Acquire Firefly Bio, Capturing Pan-KRAS Degrader Platforms for Hard-to-Treat Solid Tumors
Key Development Global healthcare leader Johnson & Johnson (J&J) has officially finalized its acquisition of biotechnology innovator Firefly Bio Inc.... Read more
Moderna Q2 2026 Financial Readout: Revenue Beats Estimates Driven by International Deals, Reduced R&D Opex, and Impending Landmark FDA Decision on mRNA Flu Vaccine
Key Development American biotechnology pioneer Moderna, Inc. (NASDAQ: MRNA) officially released its Q2 2026 financial results, exceeding Wall Street consensus... Read more
Resolving Antitrust Exposure: Sandoz Agrees to $480 Million Multi-State Settlement to Conclude U.S. Generic Price-Fixing Litigation
Key Development Basel-based generics and biosimilars leader Sandoz Group AG has formally entered into definitive settlement agreements to resolve long-standing... Read more
Re-igniting the Obesity Battle: Novo Nordisk Reclaims Market Momentum with Oral Wegovy Against Eli Lilly
Key Development Following a challenging two-year period marked by profit warnings, executive restructuring, and share price contraction, Novo Nordisk is... Read more









